| 000 | 01824 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250516031413.0 | ||
| 264 | 0 | _c20110728 | |
| 008 | 201107s 0 0 eng d | ||
| 022 | _a1473-4877 | ||
| 024 | 7 |
_a10.1185/03007995.2011.569018 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMohiuddin, Syed M | |
| 245 | 0 | 0 |
_aEvaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis. _h[electronic resource] |
| 260 |
_bCurrent medical research and opinion _cMay 2011 |
||
| 300 |
_a1067-78 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAtorvastatin |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aDyslipidemias _xblood |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFenofibrate _xadministration & dosage |
| 650 | 0 | 4 |
_aFluorobenzenes _xadministration & dosage |
| 650 | 0 | 4 |
_aHeptanoic Acids _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydroxymethylglutaryl-CoA Reductase Inhibitors _xagonists |
| 650 | 0 | 4 |
_aHypolipidemic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aLipids _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPyrimidines _xadministration & dosage |
| 650 | 0 | 4 |
_aPyrroles _xadministration & dosage |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aRosuvastatin Calcium |
| 650 | 0 | 4 |
_aSulfonamides _xadministration & dosage |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aThakker, Kamlesh M | |
| 700 | 1 | _aSetze, Carolyn M | |
| 700 | 1 | _aKelly, Maureen T | |
| 773 | 0 |
_tCurrent medical research and opinion _gvol. 27 _gno. 5 _gp. 1067-78 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1185/03007995.2011.569018 _zAvailable from publisher's website |
| 999 |
_c20708357 _d20708357 |
||